Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis - Brief Report

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 12, 2016, Pages 2421-2423

  Afshar, Mehdi ^a,b   Kamstrup, Pia R ^c   Williams, Ken ^d   Sniderman, Allan D ^a,b   Nordestgaard, Børge G ^c,e,f   Thanassoulis, George ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d KenAnCo Biostatistics   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

aortic valve stenosis; atherosclerosis; coronary disease; epidemiology; genetics; lipoproteins; prevention and control

Indexed keywords

ANTILIPEMIC AGENT; LIPOPROTEIN A; BIOLOGICAL MARKER;

AORTA VALVE STENOSIS; ARTICLE; ATTRIBUTABLE RISK; CARDIOVASCULAR RISK; HEART INFARCTION; HUMAN; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; PRIMARY PREVENTION; PRIORITY JOURNAL; AORTIC VALVE STENOSIS; BLOOD; DENMARK; DOWN REGULATION; HYPERLIPOPROTEINEMIA; PROSPECTIVE STUDY; PROTECTION; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AORTIC VALVE STENOSIS; BIOMARKERS; DENMARK; DOWN-REGULATION; HUMANS; HYPERLIPOPROTEINEMIAS; HYPOLIPIDEMIC AGENTS; INCIDENCE; LIPOPROTEIN(A); MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84992088533     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.308271     Document Type: Article

References (12)

1. Nordestgaard BG, Chapman MJ, Ray K, et al; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853. doi: 10.1093/eurheartj/ehq386.
2. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331-2339. doi: 10.1001/jama.2009.801.
3. Thanassoulis G, Campbell CY, Owens DS, et al; CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503-512. doi: 10.1056/NEJMoa1109034.
4. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470-477. doi: 10.1016/j. jacc.2013.09.038.
5. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-1509. doi: 10.1056/NEJMoa1500858.
6. Robinson JG, Farnier M, Krempf M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499. doi: 10.1056/NEJMoa1501031.
7. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL. Antisense therapy targeting apolipoprotein(a): a randomised, doubleblind, placebo-controlled phase 1 study. Lancet. 2015;386:1472-1483. doi: 10.1016/S0140-6736(15)61252-1.
8. Viney NJ, van Capelleveen JC, Geary RS, Shuting Xia, Tami JS, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raise lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials [published online ahead of print September 21, 2016]. Lancet. doi: 10.1016/S0140-6736 (16)31009-1. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31009-1/abstract.
9. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302: 412-423. doi 10.1001/jama.2009.1063.
10. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540-2544.
11. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke. 2007;38:1959-1966. doi: 10.1161/STROKEAHA.106.480657.
12. Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN, Cowan CA, Rader DJ, Musunuru K. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014;115:488-492. doi: 10.1161/CIRCRESAHA.115.304351.